EA201892313A1 - Гуманизированные антитела против clever-1 и их применение - Google Patents

Гуманизированные антитела против clever-1 и их применение

Info

Publication number
EA201892313A1
EA201892313A1 EA201892313A EA201892313A EA201892313A1 EA 201892313 A1 EA201892313 A1 EA 201892313A1 EA 201892313 A EA201892313 A EA 201892313A EA 201892313 A EA201892313 A EA 201892313A EA 201892313 A1 EA201892313 A1 EA 201892313A1
Authority
EA
Eurasian Patent Office
Prior art keywords
clever
application
antibodies against
humanized antibodies
binding
Prior art date
Application number
EA201892313A
Other languages
English (en)
Russian (ru)
Inventor
Микаель Максимов
Маркку Ялканен
Марита Вайнио
Original Assignee
Фарон Фармасьютикалз Ой
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Фарон Фармасьютикалз Ой filed Critical Фарон Фармасьютикалз Ой
Priority claimed from PCT/FI2017/050285 external-priority patent/WO2017182705A1/en
Publication of EA201892313A1 publication Critical patent/EA201892313A1/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52Assays involving cytokines
    • G01N2333/525Tumor necrosis factor [TNF]
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70539MHC-molecules, e.g. HLA-molecules
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
    • G01N2333/7151Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF]; for lymphotoxin [LT]
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
EA201892313A 2016-04-18 2017-04-18 Гуманизированные антитела против clever-1 и их применение EA201892313A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FI20165336 2016-04-18
PCT/FI2017/050285 WO2017182705A1 (en) 2016-04-18 2017-04-18 Humanized anti clever-1 antibodies and their use

Publications (1)

Publication Number Publication Date
EA201892313A1 true EA201892313A1 (ru) 2019-03-29

Family

ID=58692521

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201892313A EA201892313A1 (ru) 2016-04-18 2017-04-18 Гуманизированные антитела против clever-1 и их применение

Country Status (10)

Country Link
US (1) US10884000B2 (https=)
EP (1) EP3445786B1 (https=)
JP (2) JP7100588B2 (https=)
KR (1) KR102403660B1 (https=)
CN (1) CN109153720B (https=)
AU (1) AU2017252344B2 (https=)
BR (1) BR112018070350A2 (https=)
CA (1) CA3020418A1 (https=)
EA (1) EA201892313A1 (https=)
WO (1) WO2017182706A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210087454A (ko) 2018-11-01 2021-07-12 파론 파머수티컬스 오와이 대체 활성화되는 대식세포 상의 clever-1 발현을 억제하는데 사용하기 위한 tlr9 작용제
US20220404366A1 (en) * 2019-11-11 2022-12-22 Faron Pharmaceuticals Oy Anti-clever-1 agents for controlling the expression of cell surface markers on leucocytes, and using these to guide anti-clever-1 based cancer treatment
WO2021214382A1 (en) * 2020-04-20 2021-10-28 Faron Pharmaceuticals Oy Treatment of diseases with clever-1 inhibition in combination with an interleukin inhibitor
US20220227858A1 (en) 2021-01-18 2022-07-21 Faron Pharmaceuticals Oy Controlling of immune activation by soluble clever-1
JP2024545101A (ja) * 2021-12-07 2024-12-05 ファロン ファーマシューティカルズ オサケ ユキチュア 抗clever-1がん治療を誘導するための炎症マーカーの使用方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60316106T2 (de) * 2002-01-09 2008-05-29 Faron Pharmaceuticals Oy Gemeinsamer lymphatischer endothel- und gefässendothel-rezeptor-1 (clever-1) und seine verwendung
FI20090161A0 (fi) 2009-04-22 2009-04-22 Faron Pharmaceuticals Oy Uusi solu ja siihen pohjautuvia terapeuttisia ja diagnostisia menetelmiä
SG11201502827RA (en) 2012-11-09 2015-05-28 Transgene Sa Modulation of monocytes, or precursors thereof, differentiation
MX377858B (es) 2013-06-25 2025-03-11 Vaccinex Inc Combinación de moleculas inhibidoras de semaforina-4d con agentes inmunomoduladores y usos de los mismos.

Also Published As

Publication number Publication date
WO2017182706A1 (en) 2017-10-26
KR20180133854A (ko) 2018-12-17
JP2019521312A (ja) 2019-07-25
EP3445786C0 (en) 2023-10-04
JP7302049B2 (ja) 2023-07-03
EP3445786A1 (en) 2019-02-27
US10884000B2 (en) 2021-01-05
CN109153720A (zh) 2019-01-04
EP3445786B1 (en) 2023-10-04
CA3020418A1 (en) 2017-10-26
AU2017252344B2 (en) 2023-12-21
JP2022065088A (ja) 2022-04-26
KR102403660B1 (ko) 2022-05-30
US20190064180A1 (en) 2019-02-28
JP7100588B2 (ja) 2022-07-13
CN109153720B (zh) 2022-10-21
BR112018070350A2 (pt) 2019-01-29
AU2017252344A1 (en) 2018-10-11

Similar Documents

Publication Publication Date Title
CY1125561T1 (el) Εξανθρωπισμενα αντισωματα anti-clever-1 και χρηση αυτων
PE20191208A1 (es) Anticuerpos anti-cd73 y usos de los mismos
CY1122245T1 (el) Pd-1 αντισωμα, θραυσμα δεσμευσης αντιγονου αυτου, και ιατρικη εφαρμογη αυτου
EA202091130A1 (ru) Лиофилизованный препарат моноклонального антитела к транстиретину
MX2020012567A (es) Anticuerpos anti-ox40 y metodos de uso.
EA201892793A1 (ru) Анти-hla-g специфические антитела
EA201790339A1 (ru) Комбинированные препараты с антителами к cd40
ES2776179T3 (es) Anticuerpos dirigidos contra determinantes de la superficie de S. aureus
EA201892294A1 (ru) Антитела и композиции против tim-3
PH12016501212A1 (en) Human anti-il-33 neutralizing monoclonal antibody
EA201890162A1 (ru) Антитела к cd40 с повышенной агонистической активностью
PE20190737A1 (es) Anticuerpos anti-cd27
MX2021011167A (es) Anticuerpos humanizados anti grupo de diferenciacion 19 (cd19) humano y metodos de uso.
MD20170022A2 (ro) Anticorp monoclonal anti-CTLA4 sau fragment de legare a acestuia la antigen, compoziţie farmaceutică şi utilizarea lor
EA201792221A1 (ru) Антитела против сортилина и способы их применения
JOP20170004B1 (ar) الأجسام المضادة لببتيد بيتا النشوي مضاد N3pGlu واستخداماته
JOP20190187A1 (ar) مترافقات عقار جسم مضاد لـ ccr7
AR101846A1 (es) Anticuerpos anti-cll-1 e inmunoconjugados
AR110321A1 (es) Anticuerpos antitau y métodos de uso
NZ727024A (en) Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
BR112017009817A2 (pt) anticorpos anti-il-1beta e métodos de utilização
MX366359B (es) Anticuerpos humanizados contra la molecula de adhesion celular relacionada al antigeno carcinoembrionico 1 (ceacam1).
EA201892313A1 (ru) Гуманизированные антитела против clever-1 и их применение
WO2018089807A3 (en) Anti-cd46 antibodies and methods of use
EA202090791A1 (ru) Агонистические антитела против cd40